Education
About Us
Working with TipRanks
Follow Us
Wuxi Biologics (Cayman) Inc. (HK:2269)
:2269
Total Valuation
Wuxi Biologics (Cayman) has a market cap or net worth of $171.98B. The enterprise value is HK$103.71B.
Market Cap$171.98B
Enterprise ValueHK$103.71B
Share Statistics
Wuxi Biologics (Cayman) has 4,086,953,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,086,953,900
Owned by Insiders―
Owned by Institutions0.02%
Financial Efficiency
Wuxi Biologics (Cayman)’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 7.96%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)7.96%
Return on Capital Employed (ROCE)0.10
Revenue Per Employee1.49M
Profits Per Employee384.45K
Employee Count12,575
Asset Turnover0.33
Inventory Turnover7.25
Valuation Ratios
The current PE Ratio of Wuxi Biologics (Cayman) is 37.8. Wuxi Biologics (Cayman)’s PEG ratio is 0.00.
PE Ratio37.8
PS Ratio3.60
PB Ratio1.61
Price to Fair Value1.61
Price to FCF52.28
Price to Operating Cash Flow28.51
PEG Ratio0.00
Income Statement
In the last 12 months, Wuxi Biologics (Cayman) had revenue of 18.68B and earned 3.36B in profits. Earnings per share was 0.82.
Revenue18.68B
Gross Profit7.65B
Operating Income4.97B
Pretax Income4.83B
Net Income3.36B
EBITDA6.43B
Earnings Per Share (EPS)0.82
Cash Flow
In the last 12 months, operating cash flow was 5.72B and capital expenditures -3.96B, giving a free cash flow of 1.76B billion.
Operating Cash Flow5.72B
Free Cash Flow1.76B
Free Cash Flow per Share0.43
Dividends & Yields
Wuxi Biologics (Cayman) pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.76
52-Week Price Change96.64%
50-Day Moving Average34.59
200-Day Moving Average25.71
Relative Strength Index (RSI)68.63
Average Volume (3m)53.26M
Important Dates
Wuxi Biologics (Cayman) upcoming earnings date is Mar 31, 2026, TBA (Confirmed).
Last Earnings DateAug 19, 2025
Next Earnings DateMar 31, 2026
Ex-Dividend Date―
Financial Position
Wuxi Biologics (Cayman) as a current ratio of 2.73, with Debt / Equity ratio of 11.36%
Current Ratio2.73
Quick Ratio2.56
Debt to Market Cap0.04
Net Debt to EBITDA-0.52
Interest Coverage Ratio31.56
Taxes
In the past 12 months, Wuxi Biologics (Cayman) has paid 889.03M in taxes.
Income Tax889.03M
Effective Tax Rate0.18
Enterprise Valuation
Wuxi Biologics (Cayman) EV to EBITDA ratio is 9.95, with an EV/FCF ratio of 49.69.
EV to Sales3.43
EV to EBITDA9.95
EV to Free Cash Flow49.69
EV to Operating Cash Flow12.26
Balance Sheet
Wuxi Biologics (Cayman) has $12.54B in cash and marketable securities with $5.11B in debt, giving a net cash position of $7.43B billion.
Cash & Marketable Securities$12.54B
Total Debt$5.11B
Net Cash$7.43B
Net Cash Per Share$1.82
Tangible Book Value Per Share$10.66
Margins
Gross margin is 42.65%, with operating margin of 26.63%, and net profit margin of 17.97%.
Gross Margin42.65%
Operating Margin26.63%
Pretax Margin25.89%
Net Profit Margin17.97%
EBITDA Margin34.43%
EBIT Margin26.73%
Analyst Forecast
The average price target for Wuxi Biologics (Cayman) is $37.82, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$37.82
Price Target Upside-10.34% Downside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast16.90%
EPS Growth Forecast63.11%